Abstract
Background
Acute cervical spinal cord injury (ACSCI) is commonly complicated by spinal shock, resulting in hemodynamic instability characterized by bradycardia and hypotension that can have fatal consequences. Current guidelines recommend the use of intravenous beta and dopamine agonists, such as norepinephrine and dopamine, respectively. We sought to determine whether enteral albuterol would be a safe and feasible treatment for bradycardia without an increase in the occurrence of known side effects of albuterol in patients with ACSCI.
Methods
A retrospective review of patients with ACSCI admitted to an intensive care unit at a level I trauma center and treated with enteral albuterol was conducted. Patients were excluded for the following reasons: pure beta blocker use prior to injury, concurrent use of pacemaker, age of less than 18 years, or age more than 75 years. As part of the standard of care, all patients underwent mean arterial pressure (MAP) augmentation to reach a goal of greater than 85 mm Hg during the first 7 days post injury. All eligible patient charts were reviewed for demographic characteristics, daily minimum and maximum heart rate and MAP, and concomitant vasoactive medication use. Bradycardia and tachycardia were defined as heart rate less than 60 beats per minute (bpm) and greater than 100 bpm, respectively. Factors found to be associated with bradycardia on univariate analysis were entered into a multivariable generalized estimating equation analysis to determine factors independently associated with bradycardia during the study period.
Results
There were 58 patients with cervical ASCI (age 45 ± 18 years, 76% men) admitted between January 1, 2016, and December 31, 2017, that met the study criteria. The mean time to initiation of albuterol was 1.5 ± 1.7 days post injury, with a duration of 9.3 ± 4.5 days and a mean daily dosage of 7.8 ± 4.5 mg. Bradycardia was observed in 136 of 766 patient days (17%). There were a few episodes of hyperglycemia (1%) and tachycardia (3%), but no episodes of hypokalemia. In a multivariable analysis, female sex (P = 0.006) and American Spinal Cord Injury Association grade A, B, or C (P < 0.001) were associated with a higher risk of developing bradycardia, whereas dosage of albuterol (P = 0.009) and norepinephrine use (P = 0.008) were associated with a lower risk of developing bradycardia.
Conclusions
Albuterol administration in ASCI is a safe and feasible treatment for bradycardia, given that no significant side effects, such as hyperglycemia, hypokalemia, or tachycardia, were observed. The administration of enteral albuterol was well tolerated and, in a dose-dependent manner, associated with a lower occurrence of bradycardia. Further prospective trials for the use of enteral albuterol after SCI are warranted.
Similar content being viewed by others
References
Grigorean VT, Sandu AM, Popscu M, et al. Cardiac dysfunctions following spinal cord injury. J Med Life. 2009;2:133–45.
Kim SW, Park CJ, Kim K, et al. Cardiac arrest attributable to dysfunction of the autonomic nervous system after traumatic cervical spinal cord injury. Chin J Traumatol. 2017;20:118–21.
McKinley W, Garstang SV, Wieting JM, et al. Cardiovascular concerns in spinal cord injury. Cord Injury: eMedicine Specialties/Physical Medicine and Rehabilitation/Spinal. 2006.
Evans CH, Duby JJ, Berry AJ, et al. Enteral albuterol decreases the need for chronotropic agents in patients with cervical spinal cord injury-induced bradycardia. J Trauma Acute Care Surg. 2013;76:297–302.
Whitman CB, Schroeder WS, Ploch PJ, et al. Efficacy of aminophylline for treatment of recurrent symptomatic bradycardia after spinal cord injury. Pharmacotherapy. 2008;28(1):131–5.
Franga DL, Hawkins ML, Medeiros RS, et al. Recurrent asystole resulting from high cervical spinal cord injuries. Am Surg. 2006;72(6):525–9.
Rollstin A, Carey MC, Doherty G, et al. Oral albuterol to treat symptomatic bradycardia in acute spinal cord injury. Intern Emerg Med. 2015;11:101–5.
Deveau KM, Martin EK, King NT, et al. Challenging cardiac function post-spinal cord injury with dobutamine. Auton Neurosci. 2018;209:19–24.
Abd A, Braun N. Management of life-threatening bradycardia in spinal cord injury. Chest. 1989;95:701–2.
Funding
No funding was received for this work.
Author information
Authors and Affiliations
Contributions
Authorship contributions are as follows: Krista Lim-Hing, conception and design, data collection, analysis of results, draft and revision of article; Jennifer Massetti, data collection, analysis of results; Mehrnaz Pajoumand, data collection, analysis of results, revision of article; Shailvi Gupta, data collection; Ryne Jenkins, data collection; Mubariz Hassan, data collection; Paxton Paganelli, data collection; Gunjan Parikh, conception and design; Wan-Tsu Chang, conception and design; Gary Schwartzbauer, conception and design; Deborah Stein, conception and design; Neeraj Badjatia, conception and design, analysis of results, draft and revision of article. All authors reviewed the results and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
Dr. Badjatia reports grants from National Institutes of Health/NINDS, grants from DOD, outside the submitted work. All other authors have nothing to disclose.
Ethical Approval/Informed Consent
We confirm adherence to ethical guidelines and obtained appropriate institutional review board approval for retrospective review.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lim-Hing, K., Massetti, J., Pajoumand, M. et al. Impact of Enteral Albuterol on Bradycardic Events After Acute Cervical Spinal Cord Injury. Neurocrit Care 36, 840–845 (2022). https://doi.org/10.1007/s12028-021-01384-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-021-01384-0